Is Fennec Pharmaceuticals Inc (FENC) Stock About to Get Hot Monday?

Monday, August 10, 2020 10:57 AM | InvestorsObserver Analysts

The market has been high on Fennec Pharmaceuticals Inc (FENC) stock recently. FENC gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
Fennec Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FENC!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With FENC Stock Today?

Fennec Pharmaceuticals Inc (FENC) stock is trading at $9.60 as of 10:53 AM on Monday, Aug 10, a rise of $0.59, or 6.55% from the previous closing price of $9.01. The stock has traded between $9.33 and $9.93 so far today. Volume today is above average. So far 617,926 shares have traded compared to average volume of 393,394 shares.

To see InvestorsObserver's Sentiment Score for Fennec Pharmaceuticals Inc click here.

More About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Should Edwards Lifesciences Corp (EW) be in Your Portfolio?

Is Simulations Plus, Inc. (SLP) a Winner in the Health Information Services Industry?

Is Gossamer Bio Inc (GOSS) Stock Near the Top of the Biotechnology Industry?

Do Analysts Expect Healthequity Inc (HQY) Stock to Rise?

What is the Forecast Price for Alnylam Pharmaceuticals, Inc. (ALNY) Stock?

Where Does Wall Street Think Prestige Consumer Healthcare Inc (PBH) Stock Will Go?

Related Companies